Literature DB >> 15595946

Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Richard L Kravitz1, Naihua Duan, Joel Braslow.   

Abstract

Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence ("average effects" measured as population means) to local problems (individual patients or groups who might depart from the population average). It argues that the benefit or harm of most treatments in clinical trials can be misleading and fail to reveal the potentially complex mixture of substantial benefits for some, little benefit for many, and harm for a few. Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes. Recognizing these factors, researchers can design studies that better characterize who will benefit from medical treatments, and clinicians and policymakers can make better use of the results.

Entities:  

Mesh:

Year:  2004        PMID: 15595946      PMCID: PMC2690188          DOI: 10.1111/j.0887-378X.2004.00327.x

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  68 in total

Review 1.  The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance?

Authors:  Ted J Kaptchuk
Journal:  Ann Intern Med       Date:  2002-06-04       Impact factor: 25.391

2.  Chemoprevention of breast cancer: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

3.  Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies.

Authors:  C Schmoor; M Olschewski; M Schumacher
Journal:  Stat Med       Date:  1996-02-15       Impact factor: 2.373

4.  Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation.

Authors:  R I Horwitz; B H Singer; R W Makuch; C M Viscoli
Journal:  J Clin Epidemiol       Date:  1996-04       Impact factor: 6.437

Review 5.  Dissemination of effectiveness and outcomes research.

Authors:  D E Kanouse; J D Kallich; J P Kahan
Journal:  Health Policy       Date:  1995-12       Impact factor: 2.980

6.  Nurse-staffing levels and the quality of care in hospitals.

Authors:  Jack Needleman; Peter Buerhaus; Soeren Mattke; Maureen Stewart; Katya Zelevinsky
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

7.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

Review 8.  ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.

Authors:  G Y Lip; G D Lowe
Journal:  BMJ       Date:  1996-01-06

9.  Reporting the recruitment process in clinical trials: who are these patients and how did they get there?

Authors:  Cary P Gross; Raburn Mallory; Asefeh Heiat; Harlan M Krumholz
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

10.  The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs.

Authors:  Sally A Coulthard; Linda A Hogarth; Margaret Little; Elizabeth C Matheson; Christopher P F Redfern; Lynne Minto; Andrew G Hall
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  121 in total

1.  HETEROGENEITY IN TREATMENT EFFECT AND COMPARATIVE EFFECTIVENESS RESEARCH.

Authors:  Zhehui Luo
Journal:  China Health Rev       Date:  2011-10

Review 2.  Contribution of primary care to health systems and health.

Authors:  Barbara Starfield; Leiyu Shi; James Macinko
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  A middle way for rationing healthcare resources.

Authors:  Rudolf Klein
Journal:  BMJ       Date:  2005-06-11

4.  Threads and yarns: weaving the tapestry of comorbidity.

Authors:  Barbara Starfield
Journal:  Ann Fam Med       Date:  2006 Mar-Apr       Impact factor: 5.166

5.  Applying machine learning to predict real-world individual treatment effects: insights from a virtual patient cohort.

Authors:  Gang Fang; Izabela E Annis; Jennifer Elston-Lafata; Samuel Cykert
Journal:  J Am Med Inform Assoc       Date:  2019-10-01       Impact factor: 4.497

6.  Enhancing the net benefits of disseminating efficacious prevention programs: a note on target efficiency with illustrative examples.

Authors:  David S Salkever; Stephen Johnston; Mustafa C Karakus; Nicholas S Ialongo; Eric P Slade; Elizabeth A Stuart
Journal:  Adm Policy Ment Health       Date:  2008-03-15

7.  The relative merits of population-based and targeted prevention strategies.

Authors:  Donna M Zulman; Sandeep Vijan; Gilbert S Omenn; Rodney A Hayward
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

Review 8.  A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia.

Authors:  Tim Calton; Michael Ferriter; Nick Huband; Helen Spandler
Journal:  Schizophr Bull       Date:  2007-06-14       Impact factor: 9.306

9.  Diabetes, depression, and death: a randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT).

Authors:  Hillary R Bogner; Knashawn H Morales; Edward P Post; Martha L Bruce
Journal:  Diabetes Care       Date:  2007-08-23       Impact factor: 19.112

10.  Individual results may vary: Inequality-probability bounds for some health-outcome treatment effects.

Authors:  John Mullahy
Journal:  J Health Econ       Date:  2018-07-04       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.